TickerFacts.

Enliven Therapeutics, Inc. (ELVN): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$300.0K
Year ended 2025-12-31
$166.0K
Trailing 12 months to 2026-06-30
+14.5%
3-year compound annual growth
2022-12-31: $200.0K2023-12-31: $300.0K2024-12-31: $300.0K2025-12-31: $300.0K$300.0K
2022-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$300.0K0.0%2026-03-03, From 2025-01-01
2024-12-31$300.0K0.0%2026-03-03, From 2024-01-01
2023-12-31$300.0K+50.0%2025-03-13, From 2023-01-01
2022-12-31$200.0Kn/a2024-03-14, From 2022-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Enliven Therapeutics, Inc. (ELVN)2025-12-31$300.0K0.0%
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31$500.0K-28.6%
Ardelyx, Inc. (ARDX)2025-12-31$3.06M+48.3%
Biohaven Ltd. (BHVN)2025-12-31$9.92M+26.3%
Rapport Therapeutics, Inc. (RAPP)2025-12-31$1.02M+21.2%
Rigel Pharmaceuticals Inc (RIGL)2025-12-31$2.42M+8.4%
BGM Group Ltd. (BGM)2025-09-30$1.46M+18.3%
Olema Pharmaceuticals, Inc. (OLMA)2025-12-31$490.0K+24.7%
MoonLake Immunotherapeutics (MLTX)2025-12-31$2.62M+88.9%

Compare ELVN, RYTM, ARDX, BHVN side by side · Screen every company in Pharmaceutical Preparations ↗